Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Insmed Inc (INSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10027
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are being developed for pulmonary arterial hypertension (PAH), severe refractory asthma, for chronic inflammatory lung diseases such as non-cystic fibrosis (non-CF) bronchiectasis and for nontuberculous mycobacterial lung infection and chronic Pseudomonas aeruginosa in non-CF bronchiectasis. The company has offices in the US, the UK, Ireland, the Netherlands, Germany and France. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc (INSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Licensing Agreements 12
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Equity Offering 15
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Debt Offering 24
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc – Key Competitors 26
Insmed Inc – Key Employees 27
Insmed Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Oct 30, 2018: Insmed reports third quarter 2018 financial results and provides business update 29
Aug 02, 2018: Insmed reports second quarter 2018 financial Results and provides business update 31
May 02, 2018: Insmed Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 23, 2018: Insmed Reports Fourth Quarter 2017 Financial Results 34
Nov 02, 2017: Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update 36
Aug 03, 2017: Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update 37
May 03, 2017: Insmed Reports First Quarter 2017 Financial Results 38
May 03, 2017: Insmed Q1 net loss increases 39
Feb 23, 2017: Insmed Reports Fourth Quarter 2016 Financial Results and Provides Business Update 40
Corporate Communications 41
May 15, 2017: Insmed Announces Key Additions to its Executive Management Team 41
Clinical Trials 42
May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1007 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Insmed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9
Insmed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Insmed Enters into Agreement with National Institutes of Allergy and Infectious Diseases 11
Insmed Enters into Licensing Agreement with AstraZeneca 12
Premacure Amends Licensing Agreement with Insmed 14
Insmed Raises USD402 Million in Public Offering of Shares 15
Insmed Raises USD237.4 Million in Public Offering of Common Stock 17
Insmed Raises USD115 Million in Public Offering of Shares 19
Insmed Completes Public Offering Of Shares For US$71.8 Million 21
Insmed Completes Public Offering Of Common Stock For US$26 Million 23
Insmed Raises USD450 Million in Public Offering of 1.75% Notes Due 2025 24
Insmed Inc, Key Competitors 26
Insmed Inc, Key Employees 27
Insmed Inc, Subsidiaries 28

List of Figures
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Insmed Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Insmed Inc (INSM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fabasoft Ag:企業の戦略・SWOT・財務分析
    Fabasoft Ag - Strategy, SWOT and Corporate Finance Report Summary Fabasoft Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • China National Chemical Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary China National Chemical Corp (ChemChina) is a state-owned enterprise that develops and markets chemicals. The company offers chemical materials and specialty chemicals, agrochemicals, oil processing and refining products, basic chemicals, and rubber products. ChemChina also manufactures equi …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務情報
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Fenner PLC (FENR):企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner), a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer component …
  • Danfoss AS:企業の戦略的SWOT分析
    Danfoss AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Trumpf GmbH + Co KG:企業の戦略的SWOT分析
    Trumpf GmbH + Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Mashreqbank psc:企業の戦略・SWOT・財務情報
    Mashreqbank psc - Strategy, SWOT and Corporate Finance Report Summary Mashreqbank psc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Les Laboratoires Servier:企業の戦略・SWOT・財務分析
    Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report Summary Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Luna Innovations Inc (LUNA):企業の財務・戦略的SWOT分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • Uni-Select Inc.:企業のM&A・事業提携・投資動向
    Uni-Select Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Uni-Select Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Thomson Reuters Corporation:企業の戦略・SWOT・財務分析
    Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report Summary Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Duvel Moortgat NV:企業の戦略的SWOT分析
    Duvel Moortgat NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • AGCO Corporation:企業の戦略・SWOT・財務分析
    AGCO Corporation - Strategy, SWOT and Corporate Finance Report Summary AGCO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Moss Bros Group Plc:企業の戦略的SWOT分析
    Moss Bros Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Hsh Nordbank Private Banking:企業の戦略・SWOT・財務分析
    Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Hsh Nordbank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Mercury Systems, Inc.:企業のM&A・事業提携・投資動向
    Mercury Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercury Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • SmarTone Mobile Communications Ltd:企業の戦略的SWOT分析
    SmarTone Mobile Communications Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Taisho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products such as lipovitan D, riup, clarith, z …
  • New Silkroad Culturaltainment Limited.:企業の戦略・SWOT・財務分析
    New Silkroad Culturaltainment Limited. - Strategy, SWOT and Corporate Finance Report Summary New Silkroad Culturaltainment Limited. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆